Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Rosa Mancinelli

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Therapeutics and Clinical Risk Management|August 6, 2021
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and PharmacologyChiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra
Therapeutics and Clinical Risk Management|March 14, 2013
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimodClaudio Gasperini, Serena Ruggieri, Chiara Rosa Mancinelli, et al.
Frontiers in Neurology|January 5, 2023
Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?Rosa Cortese, Sara Mariotto, Chiara Rosa Mancinelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 6, 2018
Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?Chiara Rosa Mancinelli, C Scarpazza, G Santuccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2013
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosisLuca Prosperini, Chiara Rosa Mancinelli, Laura De Giglio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2013
Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosisLuca Prosperini, Nikolaos Petsas, Eytan Raz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumabChiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGADAlessandro Dinoto, Elia Sechi, Sergio Ferrari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 3, 2020
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World StudyLuca Prosperini, Chiara Rosa Mancinelli, Claudio Marcello Solaro, et al.
Journal of Neuroimmunology|May 23, 2020
Diagnostic features of initial demyelinating events associated with serum MOG-IgGRiccardo Orlandi, Sara Mariotto, Sergio Ferrari, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Therapeutics and Clinical Risk Management|August 6, 2021
Ocrelizumab for the Treatment of Multiple Sclerosis: Safety, Efficacy, and PharmacologyChiara Rosa Mancinelli, Nicola De Rossi, Ruggero Capra
Therapeutics and Clinical Risk Management|March 14, 2013
Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimodClaudio Gasperini, Serena Ruggieri, Chiara Rosa Mancinelli, et al.
Frontiers in Neurology|January 5, 2023
Pregnancy and antibody-mediated CNS disorders: What do we know and what should we know?Rosa Cortese, Sara Mariotto, Chiara Rosa Mancinelli, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 6, 2018
Dealing with highly active multiple sclerosis after natalizumab-associated PML: could rituximab be of help?Chiara Rosa Mancinelli, C Scarpazza, G Santuccio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 4, 2013
Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosisLuca Prosperini, Chiara Rosa Mancinelli, Laura De Giglio, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|June 13, 2013
Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosisLuca Prosperini, Nikolaos Petsas, Eytan Raz, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 5, 2020
Switching to ocrelizumab in RRMS patients at risk of PML previously treated with extended interval dosing of natalizumabChiara Rosa Mancinelli, Cristina Scarpazza, Cinzia Cordioli, et al.
Multiple Sclerosis and Related Disorders|February 26, 2022
Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGADAlessandro Dinoto, Elia Sechi, Sergio Ferrari, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|April 3, 2020
Induction Versus Escalation in Multiple Sclerosis: A 10-Year Real World StudyLuca Prosperini, Chiara Rosa Mancinelli, Claudio Marcello Solaro, et al.
Journal of Neuroimmunology|May 23, 2020
Diagnostic features of initial demyelinating events associated with serum MOG-IgGRiccardo Orlandi, Sara Mariotto, Sergio Ferrari, et al.
Pageof 2